Information Provided By: 
Fly News Breaks for November 3, 2015
PCRX
Nov 3, 2015 | 08:09 EDT
Canaccord said Pacira remains one of its best ideas following its day of meetings with management. The firm expects an FDA settlement from its warning letter within weeks, strength in Q4 for its Exparel drug, and sees enormous market potential for infiltration procedures. Canaccord reiterated its Buy rating and $78 price target on Pacira shares.
News For PCRX From the Last 2 Days
There are no results for your query PCRX
